7081.KLSE Pharmaniaga Bhd
- Market cap
- MYR 1.04B
- P/E
- 6.1x
- P/B
- 2.22x
- ROE
- 19.2%
- Dividend yield
- 2.48%
- Fundamental score
- 1.6/5
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 7081.KLSE undervalued?
Graham number7081.KLSE trades 22.6% below its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Pharmaniaga Bhd fundamental analysis
9 of 22 checks passedROE 1/2
Moderate return on equity (19.2%), between 10% and 20%.
ROA 0/1
Return on assets (3.5%) is below the industry median (3.7%).
Profit Consistency 0/2
Not profitable for at least 3 consecutive years.
Earnings Growth 5Y 1/1
Earnings per share grew over the past 5 years.
Earnings Acceleration 0/1
Last year's EPS growth (-85.3%) is not above the 5-year average (26.2% a year).
Earnings Growth vs Industry 0/1
Last year's EPS growth (-85.3%) is below the industry median (6.1%).
Revenue Growth 1/2
Revenue grew 4.1% a year over the past 3 years.
Short-term Liquidity 1/1
Current assets cover short-term liabilities.
Long-term Liabilities 1/1
Current assets cover long-term liabilities.
Debt to Equity 0/2
High debt to equity (170.3%), above 100%.
Debt Trend 0/1
Debt to equity has risen over the past 5 years.
Debt Coverage 0/1
Operating cash flow does not cover 20% of total debt.
Interest Coverage 0/1
EBIT is 4.1x against interest expense, below 5x.
PE vs Market 1/1
PE (6.1x) is below the market median (11.4x).
PE vs Industry 1/1
PE (6.1x) is below the industry median (27.9x).
PBV 0/1
Price to book (2.2x) is above the industry median (2.2x).
Graham Number 1/1
The price is below the Graham number (PE x PB = 13.5, limit 22.5).
PEG 1/1
PEG on 5-year earnings growth is 0.23, growth is cheap.
Dividend Yield 0/2
No dividend paid in the last reported year.
Dividend Stability 0/2
Dividends were not paid steadily for the past 5 years.
Dividend Growth 0/1
Dividends paid did not grow over the past 5 years.
Payout Ratio 0/1
No dividend, or no profit to pay it from.
Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score
About Pharmaniaga Bhd
Pharmaniaga Berhad, an investment holding company, operates as an integrated healthcare service provider in Malaysia, Indonesia, and internationally. The company operates through Logistics and Distribution, Manufacturing, and Indonesia segments. It is involved in manufacturing, distribution, and marketing of pharmaceutical and medical products, such as generic drugs and over-the-counter medicines; supply and installation of medical and hospital equipment; and research and de…
Full company profilePharmaniaga Bhd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Pharmaniaga Bhd annual financial statements (MYR; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 2.19B | 2.32B | 2.38B | 2.82B | 2.73B | 4.82B | 3.48B | 3.40B | 3.76B | 3.93B | 4.44B |
| Gross Profit | 343M | 335M | 322M | 341M | 295M | 630M | -210M | 308M | 540M | 409M | 461M |
| Operating Income | 105M | 101M | 105M | 93.1M | 69.5M | 310M | -520M | 694K | 278M | 130M | 168M |
| EBITDA | - | 102M | 106M | 377M | 102M | 344M | -534M | 22.5M | 302M | 169M | 206M |
| Net Income | 45.6M | 53.8M | 42.5M | -149M | 27.5M | 172M | -630M | -80.2M | 132M | 48.5M | 87.9M |
| EPS | 0.04 | 0.04 | 0.03 | -0.11 | 0.02 | 0.66 | -2.40 | -0.29 | 0.46 | 0.07 | 0.07 |
| Balance Sheet | |||||||||||
| Total Assets | 1.68B | 1.61B | 1.91B | 1.59B | 1.58B | 2.26B | 1.85B | 1.91B | 1.99B | 2.25B | 2.49B |
| Total Liabilities | 1.15B | 1.08B | 1.40B | 1.25B | 1.24B | 1.79B | 2.20B | 2.19B | 2.14B | 1.79B | 2.00B |
| Shareholders' Equity | 531M | 528M | 509M | 338M | 338M | 450M | -370M | -299M | -171M | 434M | 459M |
| Cash & Short-term Investments | 70.5M | 27.9M | 35.7M | 29.6M | 40.7M | 52.4M | 52.8M | 118M | 135M | 259M | 152M |
| Total Debt | 248K | 285M | 392M | 417M | 440M | 857M | 1.17B | 1.19B | 1.19B | 820M | 781M |
| Cash Flow | |||||||||||
| Operating Cash Flow | 35.4M | 239M | -81.8M | 190M | -25.7M | -64.1M | -142M | 47.0M | 42.7M | -17.7M | -24.1M |
| Capital Expenditure | 43.6M | 29.4M | 17.7M | 20.4M | 32.6M | 45.4M | 77.6M | 73.7M | 31.2M | 29.8M | 146M |
| Free Cash Flow | - | 161M | -154M | 169M | -58.3M | -109M | -220M | -26.7M | 11.5M | -47.5M | -170M |
| Ratios | |||||||||||
| ROE | 8.6% | 10.2% | 8.3% | -44.2% | 8.1% | 38.2% | - | - | - | 11.2% | 19.2% |
| ROA | 2.7% | 3.3% | 2.2% | -9.4% | 1.7% | 7.6% | -34.1% | -4.2% | 6.6% | 2.2% | 3.5% |
| Net Profit Margin | 2.1% | 2.3% | 1.8% | -5.3% | 1.0% | 3.6% | -18.1% | -2.4% | 3.5% | 1.2% | 2.0% |
| Debt to Equity | 0.00x | 0.54x | 0.77x | 1.23x | 1.30x | 1.90x | - | - | - | 1.89x | 1.70x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Pharmaniaga Bhd dividends
- Dividend yield
- 2.48%
- Forward dividend
- 0.02 MYR
- Payout ratio
- -
- Ex-dividend date
- Sep 14, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | MYR 7.86M | 0.03 | - |
| 2022 | MYR 82.5M | 0.31 | - |
| 2021 | MYR 58.9M | 0.23 | 34.2% |
| 2020 | MYR 26.1M | 0.02 | 95.1% |
| 2019 | MYR 40.4M | 0.03 | - |
| 2018 | MYR 39.0M | 0.03 | 91.8% |
| 2017 | MYR 41.5M | 0.03 | 77.2% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1:5 on Jun 8, 2026.
Who owns Pharmaniaga Bhd
- Insiders 62.03%
- Institutions 14.76%
- Public & others 23.22%
- Shares outstanding 1.31B
- Free float 341M
Pharmaniaga Bhd company profile
- Company name
- Pharmaniaga Bhd
- Ticker
- 7081.KLSE
- ISIN
- MYL7081OO002
- Exchange
- Kuala Lumpur Exchange
- Sector
- Healthcare
- Industry
- Health Care Providers & Services
- Employees
- 3,502
- Fiscal year end
- December
- Address
- No. 7, Lorong Keluli 1B, Shah Alam, Malaysia, 40000
- Phone
- 60 3 3342 9999
- Website
- pharmaniaga.com
About Pharmaniaga Bhd
Pharmaniaga Berhad, an investment holding company, operates as an integrated healthcare service provider in Malaysia, Indonesia, and internationally. The company operates through Logistics and Distribution, Manufacturing, and Indonesia segments. It is involved in manufacturing, distribution, and marketing of pharmaceutical and medical products, such as generic drugs and over-the-counter medicines; supply and installation of medical and hospital equipment; and research and development of pharmaceutical products. The company also produces and distributes food supplements. In addition, it distributes and trades diagnostic products; and develops OLIN digital platform, an integrated digital platform for ordering, inventory, billing, and sales operations. Further, the company provides logistics services and primary care products for acute diseases and specialty care products for serious and chronic diseases. Pharmaniaga Berhad was founded in 1994 and is based in Shah Alam, Malaysia.
Pharmaniaga Bhd management
10- Zulkifli Bin JafarDeputy CEO, Managing Director & Director · born 1972
- Ms. Norai'ni Binti Mohamed AliChief Financial Officer · born 1967
- Dr. Badarulhisam Abdul RahmanChief Scientific Officer · born 1968
- Mr. Zulhazri bin RazaliHead of Market Expansion Services · born 1967
- Dr. Imam Fathorrahman M.M.Head of Indonesia Operations · born 1964
- Ms. Wan Intan Idura Wan IsmailChief Governance Officer & Company Secretary · born 1981
- Mr. Ahmad Shahredzuan Bin Mohd ShariffChief Operating Officer · born 1983
- Mr. Raja Ahmad Hidzir Bin Raja MuhamadHead of Human Resources & Administration · born 1972
- Mr. Mohd Izwan IshakHead of Manufacturing · born 1979
- Ms. Fazleena JasinHead of Sustainability